Vivienne V. D. W.
- Country
- The Netherlands
- Department
- Privately owned research centre
Research Overview
- Baricitinib Versus TNF Inhibitors for Venous Thromboembolism Risk in Rheumatoid Arthritis: Phase 3b/4 Active-Controlled Study
- Efficacy and Safety of Tanimilast DPI as Add-On to Triple Therapy in Chronic Obstructive Pulmonary Disease with Chronic Bronchitis
- Efficacy and Safety Evaluation of Tanimilast (CHF6001) as an Add-On to Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis
Data & Insights
Has run more than one trial at 310 of 1027 partner sites.
Specializations
Neurodegenerative Disease
Focus on therapeutic strategies for cognitive decline associated with Alzheimer’s disease.
- Adjunctive therapy with acetylcholinesterase inhibitors
- Outcome measurement using ADAS-Cog
- Disease‑modifying approaches
Efforts aim to improve functional outcomes in patients with mild to moderate dementia.
Dermatology
Investigates targeted treatment for inflammatory skin conditions such as Atopic Dermatitis.
- Monoclonal antibody rocatinlimab
- Assessment with Eczema Area and Severity Index
- Validated Investigator’s Global Assessment
Clinical endpoints emphasize skin clearance and patient‑reported quality of life.
Respiratory Disease
Dedicated to advancing care for chronic airway disorders including Chronic Obstructive Pulmonary Disease and chronic bronchitis.
- Inhaled corticosteroid/LABA/LAMA triple therapy
- Reduction of moderate and severe exacerbations
- Dry powder inhaler (DPI) formulation of investigational agents
Trials assess long‑term safety and lung‑function preservation.
Metabolic & Obesity
Explores interventions for weight management and glycemic control in Type 2 diabetes and obesity.
- Combination of semaglutide and cagrilintide
- Dual agonist therapies for weight loss
- Impact on metabolic parameters
Research includes participants with and without diabetes to assess broad applicability.
Cardiovascular & Heart Failure
Focuses on preventing cardiac events in at‑risk populations, including those with hypertension and established cardiovascular disease.
- Baxdrostat with dapagliflozin
- Vicadrostat combined with empagliflozin
- Risk reduction for heart‑failure hospitalization
Endpoints target mortality, heart‑failure incidence, and vascular complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.